Comparative study of combination chemotherapies of cisplatin plus vindesine versus cisplatin plus ACNU in non-small cell lung cancer.

スポンサーリンク

概要

• 論文の詳細を見る

• A total of 184 patients with inoperable non-small cell lung cancer were included in a randomized trial comparing the activity of cisplatin plus vindesine (PV) with cisplatin plus ACNU (PN) therapy. In PV therapy, 80mg/m<SUP>2</SUP> cisplatin on day 1 and 3mg/m<SUP>2</SUP> vindesine on days 1, 8 and 15 were administered and in PN therapy, 80mg/m<SUP>2</SUP> cisplatin and 100mg/m<SUP>2</SUP> ACNU were administered on day 1. The overall response rates in 152 patients with complete evaluation were 22.9% for PV therapy and 12.2% for PN therapy and there was no significant difference between them. The survival curves were calculated in these 152 patients. The median survival time was 10 months for the PV group and 9 months for the PN group and the two-year survival rate of each group was 14.9% and 12.4% respectively with no significant difference between the two groups. Concerning PS 0-2 cases, the response rate for PV therapy was 23.4%, which was significantly higher than that for PN therapy (11.1%), but the survivals of the two groups were not significantly different.<BR>The frequencies of brain metastases within 40 weeks from the start of the therapy in both groups were of no significant difference (8.6% for the PV group and 10.3% for the PN group).<BR>As for the toxic effects, the frequency of thrombocytopenia in the PN group and the frequency of alopecia and/or peripheral neuropathy in the PV group were significantly greater than in the other group.

• 特定非営利活動法人 日本肺癌学会の論文

特定非営利活動法人 日本肺癌学会 | 論文

• 診療科からみた新しいTNM病期分類（UICC-7）の問題点と課題?画像診断からみた問題点と課題?
• 新潟県における肺がんの解析
• 慢性血栓塞栓性肺高血圧症合併肺腺癌に対する左上葉切除術を施行した1例
• 肺がん検診における判定基準の改訂（2）：B，C，D判定に関して
• 片側性多発脳神経障害（Garcin症候群）を契機に発見され，化学療法により神経症状の改善を得た小細胞肺癌の1例

もっと見る

スポンサーリンク